{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:02:25Z","timestamp":1780761745703,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA272940"],"award-info":[{"award-number":["R01CA272940"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB036030"],"award-info":[{"award-number":["R01EB036030"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01EB036955"],"award-info":[{"award-number":["U01EB036955"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive lobular breast carcinoma (ILC) has a distinct morphology and complex impact on clinical outcomes. In North America (NA) and Europe, geographic disparities in the management of ILC may contribute to stress experienced by patients. This study examined regional factors associated with ILC diagnosis that affected patient management and survivorship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 31-item questionnaire was distributed to three moderated ILC patient groups. The survey consisted of demographic, Likert, multiple choice, and free response questions. Statistical analysis included chi-squared, Mann\u2013Whitney U, and unpaired two-sample t-testing. P-values &lt;0.05 were significant. Free responses were analyzed for theme identification. The study was exempt from institutional review board approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Participants (902) responded from 18 countries in Europe (\n                      <jats:italic>n<\/jats:italic>\n                      = 267) and NA (\n                      <jats:italic>n<\/jats:italic>\n                      = 635). Stage at diagnosis in Europe vs. NA was I, 23.6 vs. 48.9%; II, 54.1 vs. 30.5%; III, 17.9 vs. 17.0%; and IV, 4.5 vs. 3.7%. European patients had more advanced disease, and initial treatment recommendations more frequently included antihormonal therapy or chemotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). European patients were less frequently offered lumpectomy (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01). European respondents reported less emotional support from family (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), employers (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.004), and healthcare providers (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). NA respondents reported decreased confidence in the accuracy of medical follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Shared themes included anxiety, lack of ILC-specific information relayed by providers, and perceived dismissal by providers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although unique differences exist between regions, negative psychological implications associated with ILC are universal. This study provides insight into opportunities for global improvement in ILC management, including improved screening approaches and psychological support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19523-2","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:57:48Z","timestamp":1774961868000},"page":"6394-6402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Alexis","family":"Graham-Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther L.","family":"Geven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Migyanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.","family":"Jeruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"2","key":"19523_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","volume":"193","author":"JA Mouabbi","year":"2022","unstructured":"Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022;193(2):253\u201364. https:\/\/doi.org\/10.1007\/s10549-022-06572-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"19523_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40487-019-00105-0","volume":"8","author":"J Luveta","year":"2020","unstructured":"Luveta J, Parks RM, Heery DM, Cheung KL, Johnston SJ. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther. 2020;8(1):1\u201311. https:\/\/doi.org\/10.1007\/s40487-019-00105-0.","journal-title":"Oncol Ther."},{"issue":"9","key":"19523_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182397","volume":"12","author":"Z Chen","year":"2017","unstructured":"Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma. PloS One. 2017;12(9):e0182397. https:\/\/doi.org\/10.1371\/journal.pone.0182397.","journal-title":"PloS One."},{"issue":"1","key":"19523_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-015-0519-x","volume":"17","author":"AE McCart Reed","year":"2015","unstructured":"McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and \u2018omics. Breast Cancer Res. 2015;17(1):12. https:\/\/doi.org\/10.1186\/s13058-015-0519-x.","journal-title":"Breast Cancer Res."},{"issue":"2","key":"19523_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clinimag.2005.09.021","volume":"30","author":"J Veltman","year":"2006","unstructured":"Veltman J, Boetes C, Van Die L, Bult P, Blickman JG, Barentsz JO. Mammographic detection and staging of invasive lobular carcinoma. Clin Imaging. 2006;30(2):94\u20138. https:\/\/doi.org\/10.1016\/j.clinimag.2005.09.021.","journal-title":"Clin Imaging."},{"issue":"3","key":"19523_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/gs.2018.10.04","volume":"8","author":"SJ Barker","year":"2019","unstructured":"Barker SJ, Anderson E, Mullen R. Magnetic resonance imaging for invasive lobular carcinoma: is it worth it? Gland Surg. 2019;8(3):237\u201341. https:\/\/doi.org\/10.21037\/gs.2018.10.04.","journal-title":"Gland Surg."},{"issue":"6","key":"19523_CR7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2214\/AJR.19.22027","volume":"215","author":"O Weaver","year":"2020","unstructured":"Weaver O, Yang W. Imaging of breast cancers with predilection for nonmass pattern of growth: invasive lobular carcinoma and DCIS-does imaging capture it all? AJR Am J Roentgenol. 2020;215(6):1504\u201311. https:\/\/doi.org\/10.2214\/AJR.19.22027.","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"19523_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/jbi\/wbad112","volume":"6","author":"K Coffey","year":"2024","unstructured":"Coffey K, Berg WA, Dodelzon K, et al. Breast radiologists\u2019 perceptions on the detection and management of invasive lobular carcinoma: most agree imaging beyond mammography is warranted. J Breast Imaging. 2024;6(2):157\u201365. https:\/\/doi.org\/10.1093\/jbi\/wbad112.","journal-title":"J Breast Imaging."},{"issue":"11","key":"19523_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","volume":"114","author":"S Oesterreich","year":"2022","unstructured":"Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511\u201322. https:\/\/doi.org\/10.1093\/jnci\/djac157.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"19523_CR10","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149\u201356. https:\/\/doi.org\/10.1186\/bcr767.","journal-title":"Breast Cancer Res."},{"issue":"5","key":"19523_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1524-4741.2007.00468.x","volume":"13","author":"UW Jayasinghe","year":"2007","unstructured":"Jayasinghe UW, Bilous AM, Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J. 2007;13(5):479\u201385. https:\/\/doi.org\/10.1111\/j.1524-4741.2007.00468.x.","journal-title":"Breast J."},{"issue":"1","key":"19523_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41523-021-00348-z","volume":"7","author":"MK Abel","year":"2021","unstructured":"Abel MK, Melisko ME, Rugo HS, et al. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021;7(1):139. https:\/\/doi.org\/10.1038\/s41523-021-00348-z.","journal-title":"NPJ Breast Cancer."},{"issue":"2","key":"19523_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11920-024-01578-1","volume":"27","author":"JC Walker","year":"2025","unstructured":"Walker JC, Patel S, Cobain EF, et al. Psychological considerations associated with lobular breast cancer. Curr Psychiatry Rep. 2025;27(2):98\u2013104. https:\/\/doi.org\/10.1007\/s11920-024-01578-1.","journal-title":"Curr Psychiatry Rep."},{"issue":"2","key":"19523_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-017-4324-3","volume":"165","author":"N Houssami","year":"2017","unstructured":"Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 2017;165(2):273\u201383. https:\/\/doi.org\/10.1007\/s10549-017-4324-3.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"19523_CR15","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1245\/s10434-025-17862-0","volume":"32","author":"RA Mukhtar","year":"2025","unstructured":"Mukhtar RA, Dimitroff K, Yau C, et al. Impact of neoadjuvant chemotherapy on surgical outcomes and conversion to node-negativity in invasive lobular breast cancer: analysis of molecularly high-risk tumors by histologic subtype on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(11):8243\u201353. https:\/\/doi.org\/10.1245\/s10434-025-17862-0.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"19523_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/00000658-200006000-00012","volume":"231","author":"MM Moore","year":"2000","unstructured":"Moore MM, Borossa G, Imbrie JZ, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg. 2000;231(6):877\u201382. https:\/\/doi.org\/10.1097\/00000658-200006000-00012.","journal-title":"Ann Surg."},{"issue":"1","key":"19523_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.03.111.","journal-title":"J Clin Oncol."},{"key":"19523_CR18","doi-asserted-by":"publisher","unstructured":"Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17(7):1862-9. https:\/\/doi.org\/10.1245\/s10434-010-0953-z","DOI":"10.1245\/s10434-010-0953-z"},{"key":"19523_CR19","doi-asserted-by":"publisher","unstructured":"Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73(6):1673-7. https:\/\/doi.org\/10.1002\/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b","DOI":"10.1002\/1097-0142(19940315)73:6<1673::aid-cncr2820730620>3.0.co;2-b"},{"issue":"3","key":"19523_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.psc.2023.04.010","volume":"46","author":"JK Penberthy","year":"2023","unstructured":"Penberthy JK, Stewart AL, Centeno CF, Penberthy DR. Psychological aspects of breast cancer. Psychiatr Clin North Am. 2023;46(3):551\u201370. https:\/\/doi.org\/10.1016\/j.psc.2023.04.010.","journal-title":"Psychiatr Clin North Am."},{"key":"19523_CR21","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: breast cancer. 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419. Accessed 14 Oct 2025."},{"key":"19523_CR22","unstructured":"American Cancer Society. American Cancer Society Recommendations for the Early Detection of Breast Cancer. 2023. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/screening-tests-and-early-detection\/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed 15 Oct 2025."},{"issue":"1","key":"19523_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/M19-2125","volume":"172","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Lerda D, Quinn C, et al. Breast cancer screening and diagnosis: a synopsis of the European breast guidelines. Ann Intern Med. 2020;172(1):46\u201356. https:\/\/doi.org\/10.7326\/M19-2125.","journal-title":"Ann Intern Med."},{"key":"19523_CR24","unstructured":"European Commission Initiative on Breast Cancer. European guidelines on breast cancer screening and diagnosis. https:\/\/cancer-screening-and-care.jrc.ec.europa.eu\/en\/ecibc\/european-breast-cancer-guidelines. Accessed 11 Oct 2025."},{"issue":"1","key":"19523_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ijc.31043","volume":"142","author":"P Basu","year":"2018","unstructured":"Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer screening in the European union member states-summary results from the second European screening report. Int J Cancer. 2018;142(1):44\u201356. https:\/\/doi.org\/10.1002\/ijc.31043.","journal-title":"Int J Cancer."},{"key":"19523_CR26","unstructured":"Canadian Task Force on Preventive Health Care. Breast caner (update) \u2013 draft recommendations (2024). https:\/\/canadiantaskforce.ca\/guidelines\/published-guidelines\/breast-cancer-update-2024. Accessed 15 Oct 2025."},{"key":"19523_CR27","unstructured":"DenseBreast-info. Country\/screening guidelines. https:\/\/densebreast-info.org\/europe\/european-screening-guidelines\/. Accessed 28 Oct 2025."},{"issue":"2","key":"19523_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ijc.33204","volume":"148","author":"N Zielonke","year":"2021","unstructured":"Zielonke N, Kregting LM, Heijnsdijk EAM, et al. The potential of breast cancer screening in Europe. Int J Cancer. 2021;148(2):406\u201318. https:\/\/doi.org\/10.1002\/ijc.33204.","journal-title":"Int J Cancer."},{"issue":"3","key":"19523_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.5410","volume":"155","author":"M Golshan","year":"2020","unstructured":"Golshan M, Loibl S, Wong SM, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results From the BrighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410. https:\/\/doi.org\/10.1001\/jamasurg.2019.5410.","journal-title":"JAMA Surg."},{"issue":"10","key":"19523_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103712","volume":"9","author":"A Gutzeit","year":"2024","unstructured":"Gutzeit A, Dubsky P, Matoori S, et al. Breast cancer in Switzerland: a comparison between organized-screening versus opportunistic-screening cantons. ESMO Open. 2024;9(10):103712. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103712.","journal-title":"ESMO Open."},{"issue":"1","key":"19523_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1258\/0969141053279130","volume":"12","author":"R Smith-Bindman","year":"2005","unstructured":"Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K. Comparing the performance of mammography screening in the USA and the UK. J Med Screen. 2005;12(1):50\u20134. https:\/\/doi.org\/10.1258\/0969141053279130.","journal-title":"J Med Screen."},{"issue":"1","key":"19523_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-010-1245-9","volume":"127","author":"T Salz","year":"2011","unstructured":"Salz T, DeFrank JT, Brewer NT. False positive mammograms in Europe: do they affect reattendance? Breast Cancer Res Treat. 2011;127(1):229\u201331. https:\/\/doi.org\/10.1007\/s10549-010-1245-9.","journal-title":"Breast Cancer Res Treat."},{"key":"19523_CR33","unstructured":"Oncodaily. Who does it better: Cancer screening USA vs Europe. https:\/\/oncodaily.com\/oncolibrary\/cancer-screening-usa-vs-europe. Accessed 22 Oct 2025."},{"issue":"3","key":"19523_CR34","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1148\/radiol.2333031484","volume":"233","author":"WA Berg","year":"2004","unstructured":"Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830\u201349. https:\/\/doi.org\/10.1148\/radiol.2333031484.","journal-title":"Radiology."},{"issue":"1","key":"19523_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiology.178.1.1984294","volume":"178","author":"DJ Hilleren","year":"1991","unstructured":"Hilleren DJ, Andersson IT, Lindholm K, Linnell FS. Invasive lobular carcinoma: mammographic findings in a 10-year experience. Radiology. 1991;178(1):149\u201354. https:\/\/doi.org\/10.1148\/radiology.178.1.1984294.","journal-title":"Radiology."},{"issue":"9","key":"19523_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.jacr.2014.03.022","volume":"11","author":"T Onega","year":"2014","unstructured":"Onega T, Hubbard R, Hill D, et al. Geographic access to breast imaging for US women. J Am Coll Radiol. 2014;11(9):874\u201382. https:\/\/doi.org\/10.1016\/j.jacr.2014.03.022.","journal-title":"J Am Coll Radiol."},{"issue":"5","key":"19523_CR37","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00330-017-5121-4","volume":"28","author":"P Clauser","year":"2018","unstructured":"Clauser P, Mann R, Athanasiou A, et al. A survey by the European society of breast imaging on the utilization of breast MRI in clinical practice. Eur Radiol. 2018;28(5):1909\u201318. https:\/\/doi.org\/10.1007\/s00330-017-5121-4.","journal-title":"Eur Radiol."},{"key":"19523_CR38","unstructured":"Rylands-Monk F. MRI survey reveals wide variations across Europe. AuntMinneEurope; 2016. https:\/\/www.auntminnieeurope.com\/clinical-news\/article\/15650219\/breast-mri-survey-reveals-wide-variations-across-europe. Accessed 15 Oct 2025."},{"key":"19523_CR39","unstructured":"Fricker J.. The story of hormonal therapy in breast cancer \u2013 an an important drug in oncology history, tamoxifen. Oncopedia: European History of Oncology; 2023. https:\/\/www.oncopedia.wiki\/contributions\/the-story-of-hormonal-therapy. Accessed 21 Dec 2025."},{"issue":"4","key":"19523_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejso.2011.12.014","volume":"38","author":"U G\u00fcth","year":"2012","unstructured":"G\u00fcth U, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol. 2012;38(4):296\u2013301. https:\/\/doi.org\/10.1016\/j.ejso.2011.12.014.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"19523_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamasurg.2014.2895","volume":"150","author":"KL Kummerow","year":"2015","unstructured":"Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9\u201316. https:\/\/doi.org\/10.1001\/jamasurg.2014.2895.","journal-title":"JAMA Surg."},{"issue":"2","key":"19523_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1207\/s15324796abm3202_3","volume":"32","author":"MA Andrykowski","year":"2006","unstructured":"Andrykowski MA, Manne SL. Are psychological interventions effective and accepted by cancer patients? standards and levels of evidence. Ann Behav Med. 2006;32(2):93\u20137. https:\/\/doi.org\/10.1207\/s15324796abm3202_3.","journal-title":"Ann Behav Med."},{"key":"19523_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100666","volume":"34","author":"M Yaghi","year":"2023","unstructured":"Yaghi M, Bilani N, Dominguez B, et al. Efficacy of chemotherapy in patients with HR+\/HER2-Invasive lobular breast cancer. Cancer Treat Res Commun. 2023;34:100666. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100666.","journal-title":"Cancer Treat Res Commun."},{"issue":"10","key":"19523_CR44","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1245\/s10434-019-07564-9","volume":"26","author":"MJ Thornton","year":"2019","unstructured":"Thornton MJ, Williamson HV, Westbrook KE, et al. Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma. Ann Surg Oncol. 2019;26(10):3166\u201377. https:\/\/doi.org\/10.1245\/s10434-019-07564-9.","journal-title":"Ann Surg Oncol."},{"key":"19523_CR45","doi-asserted-by":"publisher","DOI":"10.2196\/49452","volume":"7","author":"N Kureyama","year":"2023","unstructured":"Kureyama N, Terada M, Kusudo M, et al. Fact-checking cancer information on social media in Japan: retrospective study using Twitter. JMIR Form Res. 2023;7:e49452. https:\/\/doi.org\/10.2196\/49452.","journal-title":"JMIR Form Res."},{"issue":"11","key":"19523_CR46","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1245\/s10434-007-9588-0","volume":"14","author":"CM Balch","year":"2007","unstructured":"Balch CM, Copeland E. Stress and burnout among surgical oncologists: a call for personal wellness and a supportive workplace environment. Ann Surg Oncol. 2007;14(11):3029\u201332. https:\/\/doi.org\/10.1245\/s10434-007-9588-0.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19523-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:06Z","timestamp":1780761126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19523"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19523-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}